MicroPort CardioFlow has completed the submission of applications materials of VitaFlow Liberty™ for the EU CE certification

Shanghai, China, 28 December 2021 — MicroPort CardioFlow Medtech Corporation (MicroPort CardioFlow) recently announced that its latest transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has completed the submission of applications materials for the EU CE certification.

As a new-generation TAVI product, VitaFlow Liberty™ inherits the distinctive design of the VitaFlow®Transcatheter Aortic Valve (VitaFlow®), with an upgraded delivery system. The delivery system is comprised of an innovative double-reinforced spiral structure that ensures superior flexibility, non-directionality, and 360-degree freedom of motion during delivery, the spiral structure also allows fast, stable release and recapturing of the valve for accurate positioning.

Since the launch of VitaFlow® series of TAVI product, MicroPort CardioFlow has successfully entered into over 300 heart centers across China, becoming a major player in the Chinese heart valve market. The launch of Vitaflow Liberty™ is not just an upgrade of the delivery system with added recapturing functionality, it is a comprehensive optimization for the whole system that places the solution at the leading edge internationally. Since its launch, VitaFlow Liberty™ has received positive reviews by clinicians in China and across the globe for its unparalleled control experience and clinical results. The submission of applications materials for the EU CE certification of Vitaflow Liberty™ marks another solid step in the international expansion of CardioFlow Medtech.

With years of R&D experience and technological foundation, MicroPort CardioFlow has built an integrated platform focusing on the R&D, clinical, manufacturing and commercialization of medical devices for structural heart disease. In the future, MicroPort CardioFlow will continue to adhere to the mission of“provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases ", further leverage the advantages of the platform, to continuously accelerate the introduction of internationally leading products and progressively expand internationally.